Gland Standalone December 2022 Net Sales at Rs 925.90 crore, down 12.92% Y-o-Y
January 23, 2023 / 22:52 IST
Reported Standalone quarterly numbers for Gland Pharma are:Net Sales at Rs 925.90 crore in December 2022 down 12.92% from Rs. 1,063.33 crore in December 2021.
Quarterly Net Profit at Rs. 227.54 crore in December 2022 down 16.77% from Rs. 273.38 crore in December 2021.
EBITDA stands at Rs. 345.47 crore in December 2022 down 12.52% from Rs. 394.93 crore in December 2021.
Gland EPS has decreased to Rs. 13.82 in December 2022 from Rs. 16.64 in December 2021.
| Gland shares closed at 1,386.65 on January 20, 2023 (NSE) and has given -37.75% returns over the last 6 months and -58.03% over the last 12 months. |
| Gland Pharma | | Standalone Quarterly Results | in Rs. Cr. |
|
| Dec'22 | Sep'22 | Dec'21 | | Net Sales/Income from operations | 925.90 | 1,048.31 | 1,063.33 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 925.90 | 1,048.31 | 1,063.33 | | EXPENDITURE | | Consumption of Raw Materials | 433.20 | 504.37 | 464.58 | | Purchase of Traded Goods | 3.90 | 3.79 | 4.72 | | Increase/Decrease in Stocks | -15.85 | 17.13 | 34.12 | | Power & Fuel | -- | -- | -- | | Employees Cost | 100.52 | 101.16 | 81.43 | | Depreciation | 37.61 | 36.67 | 27.83 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 120.18 | 126.63 | 129.20 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 246.35 | 258.56 | 321.43 | | Other Income | 61.51 | 65.62 | 45.67 | | P/L Before Int., Excpt. Items & Tax | 307.86 | 324.19 | 367.10 | | Interest | 2.62 | 1.72 | 1.18 | | P/L Before Exceptional Items & Tax | 305.24 | 322.47 | 365.92 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 305.24 | 322.47 | 365.92 | | Tax | 77.70 | 82.84 | 92.53 | | P/L After Tax from Ordinary Activities | 227.54 | 239.63 | 273.38 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 227.54 | 239.63 | 273.38 | | Equity Share Capital | 16.47 | 16.47 | 16.43 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 13.82 | 14.55 | 16.64 | | Diluted EPS | 13.81 | 14.55 | 16.64 | | EPS After Extra Ordinary | | Basic EPS | 13.82 | 14.55 | 16.64 | | Diluted EPS | 13.81 | 14.55 | 16.64 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
